The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
ParodyParrot just me interpreting what Andybe4 is saying.
He is always coming out with new dates. First it was the 4th January, along with Oakleaf. Then it was a few weeks of building up Valentine's Day. And now something about Christmas and the winds not speeding things up.
That date is for peer review.
No way are they going to meet that considering results have not been published.
Andybe4 now thinks it will be Christmas time, and I have to agree with him. The high winds are not speeding things up.
Andybe4 - you spent many posts building up the 14th February and sadly, nothing came from it.
But I am with you on this one and would say results are coming next Christmas.
The wait is so terrible isn't it? Even the high winds are not speeding things up.
It is close.
For a start, just look at the lack of social media posts this month in comparison to January. Last one was beginning of the month and nothing since.
They have better things to be getting on with. Bigger messages to prepare.
Thanks for sharing HPHQ.
My understanding of early 2022 is Q1-2022 and I am happy to wait until the end of March if need be.
Peer review will not be arriving on 1st March 2022, considering top line data hasn't even been released yet.
Additional $30bn: https://www.wsj.com/articles/biden-administration-seeking-additional-30-billion-for-covid-19-response-11644963914
$4.9 billion for testing
And an incredible $17.9 billion for countermeasures such as antivirals.
The chat room on Reddit is full. Alongside the other closed boards, it is far better than this gutter.
There are a few good posters here, Manifesto, but you're certainly not one of them.
TR1!!! NEWS IMMINENT! STAND BY FOR ROCKET LAUNCH.
No thanks.
What are you on about Manifesto?
This is not the first time I have heard about such things and secondly, who are you to call anyone out with your incessant postings about imminent TR1's / RNS's blah blah blah
They list every single company they have held discussions with.
Synairgen are on there because they qualify for "COVID-19 treatments that have received EMA advice".
That being said, EU ministers are meeting for a new covid plan and more money:
https://ec.europa.eu/commission/presscorner/detail/en/IP_22_1061
“The objective is to help coordinate actions and mobilise resources in six priority areas in relation to the global COVID-19 response to bring an end to the pandemic by the end of 2022: get shots in arms, bolster supply chain resilience, address information gaps, support health care workers, ensure availability of treatments and testing where it is most needed and strengthen the global health security architecture.”
From the article, this is the key paragraph:
"De-risked assets that have cleared pivotal trials and are on the path to market will appeal to Big Pharma because the behemoths can handle the commercial, regulatory and supply chain risks better than budding biotechs can.”
Yesterday's news - US Gov preparing to budget $17.9 billion for medical countermeasures such as antivirals:
https://www.wsj.com/articles/biden-administration-seeking-additional-30-billion-for-covid-19-response-11644963914
NIH recently reclassified interferons from immunomodulator to antiviral https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/interferons/
Anti-viral pills "sat on shelves" https://www.beckershospitalreview.com/supply-chain/highly-anticipated-covid-19-antivirals-now-sit-on-shelves.html
Important to note, the values of the pre-orders for those anti-viral pills:
Paxlovid: $5,295,000,000.00 (November 17, 2021)
Paxlovid: $442,132,500.00 (January 9, 2022)
Molnupiravir: $1,200,000,000 (June 7, 2021)
Molnupiravir: $588,999,864.00 x 2 (November 5, 2021)
With a potential $17.9 billion sloshing around and many of those pills sat on the shelves, what would you be ordering if you were the US Gov (BARDA)?
Mr Costs:
You claim to have 160k shares worth of Synairgen. By anyone's standards, that is a lot of money. One would assume that a person purchasing 160k shares in any company has at least some conviction in their trade.
You however, not only lack conviction in your trade, but you also lack basic understand as to what constitutes an update from the company in 2022.
Let me help you: https://oneashfield.com/blog/ashfield-engage-announces-global-strategic-partnership-with-synairgen/
Dated 7th January 2022 which the current year.